

ESPERION 2Q20 CONFERENCE CALL

August 10, 2020



SAFE HARBOR

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the clinical development and commercialization plans for bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet, including Esperion's timing, designs, plans for announcement of results regarding its CLEAR Outcomes study, timing for the review and approval of expanded indications for their effect on cardiovascular events, and Esperion's expectations for the market for medicines to lower LDL-C, including the commercial launch and market adoption of bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet in the United States and European Union. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, delays or failures in Esperion's clinical development and commercialization plans, or approval of expanded indications, that existing cash resources may be used more quickly than anticipated, that Otsuka is able to successfully commercialize bempedoic acid and the bempedoic acid / ezetimibe fixed dose combination tablet, the impact of COVID-19 on our business, clinical activities and commercial development plans, and the risks detailed in Esperion's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.



Unprecedented Times



Extraordinary Quarter

Esperion is Stronger Than Ever

Highlights



Two
Launches



Growing
Rx Trends



Adapted to
COVID-19



Managed
Care
Coverage



New Ways of
Engaging



Ex-U.S.
Partnerships

Headwinds



COVID-19
Pandemic



Limited HCP
Interactions

Prescription Trajectory and HCP Interactions are Trending up in July

Ever Expanding Opportunities for Future Value Creation

**Commercial
Agreements**

**CLEAR Outcomes
Progress**

**Franchise
Expansion**

A close-up, low-angle shot of a person's hand resting on a steering wheel. The hand is in the foreground, slightly out of focus, with the fingers wrapped around the top of the wheel. The background is a bright, hazy sunset or sunrise, with the sun low on the horizon, creating a strong lens flare and illuminating the scene with warm, golden light. The sky is a mix of blue and orange. In the lower-left corner, there is white text. The steering wheel and dashboard are visible in the foreground, with a speedometer showing numbers like 80, 100, 120, 140, and 160 km/h.

**Every Day,
We Have More
Reasons to Believe in
What's Ahead**

Beginning to Ascend, All Systems Clear



**Differentiated
Pricing,
Positioning
& Messaging**




**Broad, High
Quality
Managed
Care
Coverage**




**Health Care
Provider
Engagement &
Education**

Broad and High-Quality Payor Coverage Ahead of Expectations and Other Launches

Payor Coverage Exceeds One Year




Coverage is in Preferred Tiers with Lower Patient Costs






Increasing HCP Contact Results in Double Prescriptions from June to July



Despite Pandemic, NEXLETOL® and NEXLIZET™ Prescription Volume Surpassed Combined PCSK9i



Source: IQVIA/Symphony Health

An aerial photograph of a river delta with intricate, branching water channels and sandy islands. Three rectangular boxes are overlaid on the image: a light blue box on the left, a medium blue box in the center, and a dark blue box on the right. Each box contains white text describing a different revenue stream.

**U.S. Net
Product Sales**

**Ex-U.S.
Collaboration
Milestones**

**Ex-U.S.
Royalty
Revenues**

**Strong Cash Position with Diversified Revenue
Streams**




**\$214 Million
in First Half Revenue**

**Highest Quarterly and First Half Total
Revenue in Company History**

Significant Cash Resources to Support Launches

\$300M+ in Cash at 6/30/20



Key Financial Data

FY 2019 Revenue	\$148.4M
FY 2020 Revenue	No Guidance Provided
FY 2020 Milestone Cash Proceeds	<p>> \$235M</p> <ul style="list-style-type: none"> Future capital available upon the completion of an ex-US ROW collaboration (4Q 2020)
FY Op Ex Guidance*	\$335 - \$355M
Anticipated Cash Balance at Dec. 31, 2020	> \$100M
Common Shares Outstanding	Basic 27.8M; Fully Diluted 32.8M

*Excludes \$30M of non-cash stock based compensation expense

In Many Ways, We are all Stronger than Ever



Thank You Questions?



Tim Mayleben
CEO & President



Mark Glickman
CCO



Rick Bartram
CFO